StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Equities researchers at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued on Friday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.56 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The company has a market cap of $86.70 million, a P/E ratio of -1.20 and a beta of 3.08. The stock has a 50-day moving average of $1.80 and a two-hundred day moving average of $1.99. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The business had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the prior year, the business earned ($0.31) EPS. As a group, analysts anticipate that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Long Focus Capital Management LLC boosted its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the period. First Affirmative Financial Network purchased a new position in Cellectis during the 3rd quarter worth $45,000. Finally, XTX Topco Ltd acquired a new position in Cellectis in the second quarter valued at $29,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.